NCT05897190已完成1 期
Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine (RBMRNA-405) as a Booster in Chinese Adults & Older
Argorna Pharmaceuticals Co., LTD1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2022年5月16日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 60
- 试验地点
- 1
- 主要终点
- Incidence of solicited local and systemic adverse events (AE)
研究概览
简要总结
This study is to evaluate the safety and immunogenicity of a SARS-CoV-2 mRNA Vaccine as a heterologous booster dose in adults who completed 2 doses of inactivated vaccination through 12 months in China.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Adults aged 18 years and older, Body Mass Index (BMI) is between 18-30, able to provide legal proof of identity
- •Participants voluntarily agreed to participate in the study and signed an informed consent form
- •The subject has the ability to understand the study process and is willing and able to comply with all study proposals and other requirements of the study
- •Be willing and able to comply with protocol and complete 12-month study follow-up
- •Have received 2 doses of inactivated SARS-CoV-2 vaccine for 6 months and less than 12 months before enrollment
- •Male and female subjects of childbearing age agree to use effective contraception from screening period until 12 months after vaccination; female subjects of childbearing age have taken effective contraceptive measures 1 month before enrollment
- •Female subjects of childbearing age are not at pregnant period (negative result of pregnancy test) or lactation period
- •Male and female subjects of child-bearing age agree that do not donate eggs (eggs, oocytes) for assisted reproduction (female subjects of reproductive age) or avoid sperm donation (male subjects) from screening period until 12 months after vaccination
排除标准
- •Have received any SARS-CoV-2 vaccines other than 2 doses of the inactivated vaccine
- •History of Severe Acute Respiratory Syndrome (SARS), Coronavirus disease 2019 (COVID-19), Middle East Respiratory Syndrome (MERS) and other human coronavirus infections or disease
- •Positive SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) test
- •The vital signs or physical examination are clinically significant abnormal as determined by the investigators in screening
- •Fever (axillary temperature≥37.3°C) on the day of the vaccination
- •A history of severe allergy (including drugs, vaccines, and foods) or to any component of the experimental vaccine, e.g., allergic shock, laryngeal edema, anaphylactoid purpura, dyspnea, and angioedema, etc.
- •Subjects have contraindications to intramuscular injection, such as having been diagnosed with thrombocytopenia, any blood clotting disorder, or receiving anticoagulant therapy
- •Subjects have been diagnosed with a serious disease, congenital malformation or chronic disease (including but not limited to respiratory disease or bronchitis such as asthma, serious cardiovascular disease, serious cerebrovascular disease, kidney disease, serious or uncontrollable diabetes, autoimmune disease, thrombocytopenic purpura, thalassemia, malignant tumor, hereditary allergic constitution, etc.) that may interfere with the conduct or completion of the study
- •Diagnosed with diseases may affect immune system function, including malignant tumor, congenital or acquired immune deficiency or suppression (e.g., tuberculosis, human immunodeficiency virus (HIV)), Hepatitis B, hepatitis C, syphilis infection, uncontrollable autoimmune disease, no spleen or spleen dysfunction
- •History or family history of central nervous system disease, convulsions or tics, epilepsy, meningitis, neurological disorders, mental disorders, cerebritis, myelitis, Guillain-Barre syndrome, etc
- •Long-term use of immunopotentiator or immunosuppressant therapy within 6 months prior to vaccination (continuous oral or injection for more than 14 days)
- •Use of any blood or blood-related products (e.g., blood transfusion, use of human albumin, human immunoglobulin, etc.) or have received solid organ or bone marrow transplantation within 3 months prior to vaccination
- •Lymph node - related diseases (such as lymphadenitis, lymph node adhesion, lymph node tuberculosis, tumor metastasis, etc.) or skin scars and fistulas at the lymph node site, or lymphadenopathy, tenderness, skin redness and swelling at the lymph node site within 7 days prior to vaccination
- •Within 3 days prior to vaccination, an acute illness or attack of a chronic disease, or the use of antipyretic analgesic or anti - allergic drugs
- •Other vaccines have been administered within 4 weeks prior to the trial vaccination or other vaccination schedule (except for emergency vaccinations such as Rabies vaccine and Tetanus vaccine) between the screening period and 28 days after the vaccination
- •Participating in or planning to participate in other clinical trials (drugs or vaccines) within 3 months prior to participating in this study
- •Any blood loss >400 mL (e.g., donation of blood or blood components or injury) within 28 days prior to the screening visit, or plans to donate blood or blood components between the screening visit and 28 days post-vaccination
- •Any abnormal or permanent body art (such as tattoos) at the site of the vaccination, which the researchers think to interfere with observing local reactions at the site of the vaccination
- •Other circumstances considered by the investigator as inappropriate to participate in the study
结局指标
主要结局
Incidence of solicited local and systemic adverse events (AE)
时间窗: Within 14 days after booster vaccination
次要结局
- The levels of Immunoglobulin G (IgG) antibody against the S protein of SARS-CoV-2(The 7th day, 14th day, 28th day, 90th day, 180th day and 360th day after booster vaccination)
- The levels of neutralizing antibodies anti-SARS-CoV-2(The 14th day, 28th day after booster vaccination)
- Incidence of serious adverse events (SAEs)(Within 360 days after booster vaccination)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy PopulationSARS-CoV-2NCT04649021BioNTech SE960
进行中（未招募）
不适用
A Cohort Study of COVID-19 mRNA Vaccine, Bivalent in Participants in ChinaSARS-CoV-2NCT05547243AIM Vaccine Co., Ltd.350
已完成
1 期
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b1) in Chinese Healthy SubjectsSARS-CoV-2NCT04523571BioNTech SE144
已完成
1 期
B-pVAC-SARS-CoV-2: Study to Prevent COVID-19 Infection in Adults With Bcell/ Antibody DeficiencyImmune Deficiency DiseaseNCT04954469University Hospital Tuebingen54
已完成
4 期
SARS-CoV-2 Immune Responses After COVID-19 Therapy and Subsequent VaccineCovid19SARS-CoV2 InfectionNCT04952402National Institute of Allergy and Infectious Diseases (NIAID)43